Pay Per View: Why Fees for DTC Might Fly

The pharma industry is promising to preclear its ads with FDA. The problem is, FDA's ad review group is already overworked. Some in industry think the answer is to expand the user fee program to include fees for DTC.

PhRMA has recently promulgated new guidelines for members on responsible direct-to-consumer advertising, and one of the principles states that any DTC ads should be submitted for FDA review prior to dissemination. (See "The New Economics of DTC: Responsibility Sells," The RPM Report, April 2006 Also see "The New Economics of DTC: Responsibility Sells" - Pink Sheet, 1 April, 2006..)

There is only one problem: who is going to review all of those ads at FDA? Right now the agency...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet